Thornburg Core Plus Bond Fund - Class R6 (THCSX) News

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients

Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the...

Form PRE 14A - Other preliminary proxy statements

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 PR...

Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update

Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update PR Newswire PONTE VEDRA, Fla., May 9, 2024...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024

Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity...

Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts

Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism...

Form 8-K - Current report

Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update

Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update PR Newswire PONTE VEDRA, Fla., March 11...

Form 8-K - Current report

Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference

Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference PR...

Form 8-K/A - Current report: [Amend]